Canadian gamma camera manufacturer IS2 Research reported this month that the Food and Drug Administration has cleared its two digital single-head gamma cameras for commercialization. The cameras, NuCamma C+ and NuCamma Rx, were designed by
Canadian gamma camera manufacturer IS2 Research reported this month that the Food and Drug Administration has cleared its two digital single-head gamma cameras for commercialization. The cameras, NuCamma C+ and NuCamma Rx, were designed by founder Iain Stark, formerly of Park Medical. They were introduced at this years Society of Nuclear Medicine meeting (SCAN 8/5/98).
NuCamma C+ has a circular field of view, while NuCamma Rx is a rectangular system. The electronics of both units are incorporated into their detectors, and the systems will carry list prices between $150,000 and $190,000. The Nepean, Ontario-based company has almost completed the manufacturing of its first batch of 10 cameras.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.